A study published in Cell revealed that activated Bifidobacterium infantis EVC001 programs immune cells to control inflammation and autoimmune disease risk. Breastfed infants fed this strain experienced reduced systemic inflammation and improved immune system development.
A new study reports that activated B. infantis EVC001 improves health outcomes in preterm infants by reducing enteric inflammation, diaper rash, and antibiotic use. The probiotic also enhances gut microbial composition and reduces pathogenic bacteria, leading to improved clinical outcomes.
Approximately nine out of ten US infants suffer from a gut microbiome deficiency, including a lack of Bifidobacterium longum subsp. infantis, which plays a critical role in infant health and development. This deficiency is linked to an increased presence of antibiotic-resistant bacteria, such as Escherichia coli, and a higher risk of a...
A recent study provides genetic insights into Bifidobacterium infantis strains, revealing that strain EVC001 has a unique mechanism of action to optimize human milk metabolism and maximize health benefits in infants. The findings suggest that strain selection is crucial for maximizing impact on short- and long-term health outcomes.
A novel epigenetic diagnostic approach enables early detection of primary immune deficiencies in newborns, including Severe Combined Immunodeficiencies and X-linked agammaglobulinemia. The technology also shows promise for improving HIV treatment in low-resource countries by accurately monitoring immune cell counts on dried blood samples.